Assessment of Biomarker Profile in Diabetic Macular Edema With Intravitreal Aflibercept Injection

Status unconfirmed

Conditions studied: Diabetic Macular Edema

In brief

To assess the biomarker profile in diabetic macular edema patients in response to intravitreal aflibercept injection. Patients with diabetic macular edema who meet study requirements will receive monthly intravitreal injections of aflibercept as approved by FDA for a period of 6 months. A small quantity of fluid will be removed from the vitreous at each injection for laboratory evaluation of biomarkers present before, during and after treatment with aflibercept.

Key facts

Study ID
NCT03297684
Run by
Advanced Eye Research Associates
People needed
40
Starts
2018-04-11
Expected to finish
2022-12-31
Last updated by the study team
2022-02-18

Who can join

Age: 18 and older, up to 89. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.